Socioeconomic inequalities are still a barrier to full child vaccine coverage in the Brazilian Amazon: a cross-sectional study in Assis Brasil, Acre, Brazil

Table 2 Prevalence of vaccine coverage, valid doses and length of delay for all doses included in the first year of life, Assis Brasil, 2010

Vaccine and dose	N	Children that took the dose		Proper age (in days) for a valid dose	Prevalence of valid doses^a,bn %		Average days of delay	Minimum days of delay	Maximum days of delay
		n	%		N	%
BCG	282	281	99.7	1	202	72.2	25.7	1.5	501
HepB 1st dose	281	280	99.6	1	213	76.1	19.5	1	995
HepB 2nd dose	281	274	97.5	30	194	70.8	30.6	5	629
HepB 3rd dose	281	266	94.7	180	137	51.5	55.2	16.5	838
DTP-Hib 1st dose	281	268	95.4	60	158	59.2	32.0	7	934
DTP-Hib 2nd dose	281	263	93.6	120	159	60.7	35.5	8	888
DTP-Hib 3rd dose	281	256	91.1	180	158	62.0	33.2	7	373
OPV 1st dose	281	276	98.2	60	166	60.1	41.3	7	1520
OPV 2nd dose	281	271	96.4	120	166	61.3	39.6	8	888
OPV 3rd dose	281	260	92.5	180	153	58.8	37.0	9	705
ORV 1st dose	221	152	69.1	60	96	63.2	23.2	5	550
ORV 2nd dose	221	116	52.7	120	83	71.6	13.4	3	383
Yellow Fever	281	266	94.7	270	106	39.8	69.5	16	1028
MMR	281	256	91.1	365	99	38.7	68.6	18	854
Hepatitis B (3 doses)	281	266	94.7		78	28.2
ORV (2 doses)	221	116	52.7		67	47.2
OPV (3 doses)	281	260	92.5		75	27.9
DTP-Hib (3 doses)	281	256	91.1		78	29.8
Complete vaccine status for the first year of life ^c	282	233	82.6		6	2.3

The table depicts the number of children that took each vaccine dose, frequency of valid doses (taken until 7 days after the ideal age in days) and age (in days) considered adequate for a valid dose, and time of delay (average, minimum and maximum days of delay). The lower portion of the table shows summarized data for vaccines that require multiple doses (HBV, ORV, OPV and DTP-Hib). The last line show how many children had completed their vaccination for the first year of life, taking into account all doses received until the date of the interview, except for ORV doses. ^aValid dose = taken until 7 days after the ideal age in days; ^b only doses with a understandable date were computed; ^c ORV doses not included.

ISSN: 1475-9276